Radiotherapy-related changes in serum proteome patterns of head and neck cancer patients; the effect of low and medium doses of radiation delivered to large volumes of normal tissue

Journal of Translational Medicine

Krzysztof Składowski¹  Rafał Tarnawski¹  Andrzej Wygoda¹  Agnieszka Gdowicz-Kłosok¹  Magdalena Kalinowska-Herok²  Karol Jelonek²  Tomasz Rutkowski¹  Joanna Polańska³  Monika Pietrowska¹  Piotr Widłak¹ 

[1] Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland;Polish-Japanese Institute of Information Technologies, Warszawa, Poland;Institute of Automatics Control, Silesian University of Technology, Gliwice, Poland

关键词: Serum proteome;    Radiation toxicity;    IMRT;    Head and neck cancer;    Dose effects;   

Others  :  824380
DOI  :  10.1186/1479-5876-11-299

 received in 2013-06-28, accepted in 2013-11-25,  发布年份 2013

【 摘 要 】

Background

Conformal intensity-modulated radiation therapy (IMRT) involves irradiation of large volume of normal tissue with low and medium doses, biological relevance of which is not clear yet. Serum proteome features were used here to study the dose-volume effects in patients irradiated with IMRT due to head and neck cancer.

Methods

Blood samples were collected before and during RT, and also about one month and one year after the end of RT in a group of 72 patients who received definitive treatment. Serum proteome profiles were analyzed using MALDI-ToF mass spectrometry in 800–14,000 Da range.

Results

Major changes in serum proteome profiles were observed between pre-treatment samples and samples collected one month after RT. Radiation-related changes in serum proteome features were affected by low-to-medium doses delivered to a large fraction of body mass. Proteome changes were associated with intensity of acute radiation toxicity, indicating collectively that RT-related features of serum proteome reflected general response of patient’s organism to irradiation. However, short-term dose-related changes in serum proteome features were not associated significantly with the long-term efficacy of the treatment.

Conclusions

The effects of low and medium doses of radiation have been documented at the level of serum proteome, which is a reflection of the patient’s whole body response.

【 授权许可】

   
2013 Widłak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al.: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-854.
• [2]Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, et al.: Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:706-713.
• [3]Epstein JB, Schubert MM: Oropharyngeal mucositis in cancer therapy. Oncology 2003, 17:1767-1779.
• [4]Halperin EC, Perez CA, Brady LW: Perez and Brady’s Principles and Practice of Radiation Oncology. 5th edition. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2008.
• [5]Deasy JO, Fowler JF: Radiobiology of IMRT. In Intensity Modulated Radiation Therapy. A Clinical Perspective. Edited by Mundt AJ, Roeske JC. Hamilton: BC Decker Inc; 2005:53-74.
• [6]De Neve W, De Gersem W, Madani I: Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol 2012, 22:40-49.
• [7]Liotta LA, Ferrari M, Petricoin EF: Clinical proteomics: written in blood. Nature 2003, 425:905.
• [8]Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mangé A: Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 2006, 3:311-320.
• [9]Palmblad M, Tiss A, Cramer R: Mass spectrometry in clinical proteomics – from the present to the future. Proteomics Clin Appl 2009, 3:6-17.
• [10]Pietrowska M, Widlak P: MALDI-MS-based profiling of serum proteome: detection of changes related to progression of cancer and response to anticancer treatment. Int J Proteomics 2012, 2012:e926427.
• [11]Ménard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, et al.: Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 2006, 66:1844-1850.
• [12]Widlak P, Pietrowska M, Wojtkiewicz K, Rutkowski T, Wygoda A, Marczak L, et al.: Radiation-related changes in serum proteome profiles detected by mass spectrometry in blood of patients treated with radiotherapy due to larynx cancer. J Radiat Res 2011, 52:575-581.
• [13]Dische S: The uniform reporting of treatment-related morbidity. Seminars Radiat Oncol 1994, 4:112-118.
• [14]Wygoda A, Maciejewski B, Skladowski K, Hutnik M, Pilecki B, Golen M, et al.: Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys 2009, 73:384-390.
• [15]Hilario M, Kalousis A, Pellegrini C, Müller M: Processing and classification of protein mass spectra. Mass Spectrometry Review 2006, 25:409-449.
• [16]Pietrowska M, Marczak Ł, Polańska J, Behrendt K, Nowicka E, Walaszczyk A, et al.: Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Translat Med 2009, 7:e60. BioMed Central Full Text
• [17]Pietrowska M, Polanska J, Suwinski R, Wideł M, Rutkowski T, Marczyk M, et al.: Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression. Int J Oncol 2012, 40:148-156.
• [18]Hastie T, Tibshirani R, Friedman JH: The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York: Springer Verlag; 2009.
• [19]Lustgarten JL, Kimmel C, Ryberg H, Hogan W: EPO-KB: a searchable knowledge base of biomarker to protein links. Bioinformatics 2008, 24:1418-1419.
• [20]Pietrowska M, Polanska J, Marczak Ł, Behrendt K, Nowicka E, Stobiecki M, et al.: Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early stage breast cancer. J Translat Med 2010, 8:e66.